MR BIOINVEST ApS

 

Quicksearch
from your own companies




Analyst: XBRLDenmark
Estimate generation in progress, please wait...
 
Loading...

Loading...

Loading...

Loading...

 
Loading...

Bankruptcy Risk 
2019
2019/12
2020
2020/12
2021
2021/12
2022
2022/12
2023
2023/12
Bankruptcy risk for industry  1.5% 1.5% 1.5% 1.5% 1.5%  
Bankruptcy risk  0.5% 1.0% 0.5% 0.8% 0.5%  
Credit score (0-100)  98 85 99 91 99  
Credit rating  AA A AA A AA  
Credit limit (kDKK)  2,311.4 1,086.3 2,577.8 1,891.0 2,492.7  

How are these values calculated?
 
View the automatically generated explanation of bankruptcy risk

Income statement (kDKK) 
2019
2019/12
2020
2020/12
2021
2021/12
2022
2022/12
2023
2023/12

Net sales  0 0 0 0 0  
Gross profit  -33.0 -82.0 -34.0 -28.0 -30.7  
EBITDA  -33.0 -82.0 -34.0 -28.0 -30.7  
EBIT  -33.0 -82.0 -34.0 -28.0 -30.7  
Pre-tax profit (PTP)  3,289.0 -102.0 3,500.0 -3,273.0 2,390.0  
Net earnings  2,865.0 -102.0 2,746.0 -2,554.0 1,861.8  
Pre-tax profit without non-rec. items  3,289 -102 3,500 -3,273 2,390  

 
See the entire income statement

Balance sheet (kDKK) 
2019
2019/12
2020
2020/12
2021
2021/12
2022
2022/12
2023
2023/12

Tangible assets total  0.0 0.0 0.0 0.0 0.0  
Shareholders equity total  23,094 22,991 25,737 23,183 25,045  
Interest-bearing liabilities  0.0 37.0 73.0 73.0 72.6  
Balance sheet total (assets)  23,291 23,054 26,525 23,977 25,143  

Net Debt  -20,295 -17,129 -18,404 -14,023 -14,546  
 
See the entire balance sheet

Volume 
2019
2019/12
2020
2020/12
2021
2021/12
2022
2022/12
2023
2023/12

Net sales  0 0 0 0 0  
Net sales growth  0.0% 0.0% 0.0% 0.0% 0.0%  
Gross profit  -33.0 -82.0 -34.0 -28.0 -30.7  
Gross profit growth  48.4% -148.5% 58.5% 17.6% -9.6%  
Employees  0 0 0 0 0  
Employee growth %  0.0% 0.0% 0.0% 0.0% 0.0%  
Employee expenses  0.0 0.0 0.0 0.0 0.0  
Balance sheet total (assets)  23,291 23,054 26,525 23,977 25,143  
Balance sheet change%  15.0% -1.0% 15.1% -9.6% 4.9%  
Added value  -33.0 -82.0 -34.0 -28.0 -30.7  
Added value %  0.0% 0.0% 0.0% 0.0% 0.0%  
Investments  0 0 0 0 0  

Net sales trend  0.0 0.0 0.0 0.0 0.0  
EBIT trend  -4.0 -5.0 -5.0 -5.0 -5.0  

Profitability 
2019
2019/12
2020
2020/12
2021
2021/12
2022
2022/12
2023
2023/12
EBITDA %  0.0% 0.0% 0.0% 0.0% 0.0%  
EBIT %  0.0% 0.0% 0.0% 0.0% 0.0%  
EBIT to gross profit (%)  100.0% 100.0% 100.0% 100.0% 100.0%  
Net Earnings %  0.0% 0.0% 0.0% 0.0% 0.0%  
Profit before depreciation and extraordinary items %  0.0% 0.0% 0.0% 0.0% 0.0%  
Pre tax profit less extraordinaries %  0.0% 0.0% 0.0% 0.0% 0.0%  
ROA %  15.2% 3.6% 14.3% 6.3% 9.8%  
ROI %  15.3% 3.7% 14.5% 6.5% 9.9%  
ROE %  13.2% -0.4% 11.3% -10.4% 7.7%  

Solidity 
2019
2019/12
2020
2020/12
2021
2021/12
2022
2022/12
2023
2023/12
Equity ratio %  99.2% 99.7% 97.0% 96.7% 99.6%  
Relative indebtedness %  0.0% 0.0% 0.0% 0.0% 0.0%  
Relative net indebtedness %  0.0% 0.0% 0.0% 0.0% 0.0%  
Net int. bear. debt to EBITDA, %  61,500.0% 20,889.0% 54,129.4% 50,082.1% 47,420.5%  
Gearing %  0.0% 0.2% 0.3% 0.3% 0.3%  
Net interest  0 0 0 0 0  
Financing costs %  0.0% 5,108.1% 63.6% 6,667.1% 18.6%  

Liquidity 
2019
2019/12
2020
2020/12
2021
2021/12
2022
2022/12
2023
2023/12
Quick Ratio  103.0 275.5 23.4 19.1 154.9  
Current Ratio  103.0 275.5 23.4 19.1 154.9  
Cash and cash equivalent  20,295.0 17,166.0 18,477.0 14,096.0 14,618.8  

Capital use efficiency 
2019
2019/12
2020
2020/12
2021
2021/12
2022
2022/12
2023
2023/12
Trade debtors turnover (days)  0.0 0.0 0.0 0.0 0.0  
Trade creditors turnover (days)  0.0 0.0 0.0 0.0 0.0  
Current assets / Net sales %  0.0% 0.0% 0.0% 0.0% 0.0%  
Net working capital  914.0 361.0 -310.0 1,216.0 859.0  
Net working capital %  0.0% 0.0% 0.0% 0.0% 0.0%  

Employee efficiency 
2019
2019/12
2020
2020/12
2021
2021/12
2022
2022/12
2023
2023/12
Net sales / employee  0 0 0 0 0  
Added value / employee  0 0 0 0 0  
Employee expenses / employee  0 0 0 0 0  
EBITDA / employee  0 0 0 0 0  
EBIT / employee  0 0 0 0 0  
Net earnings / employee  0 0 0 0 0